Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. Eli Lilly and Co. (LLY:NYSE) today annou...
Streetwise Reports | June 17, 2020 |

Biopharma Continues 'Positive Push Forward in Breast Cancer'

The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. In a Dec. 26 research note, analyst Joseph Pantginis reported that H.C. Wainwright & Co. increased its target price to AU$0.20 from AU$0.16 and maintained its Buy recommen...
Streetwise Reports | December 30, 2019 |